casirivimab/imdevimab
Sign in to saveAlso known as REGN-COV2, REGN-COV, Ronapreve, REGN10933/REGN10987
Casirivimab/imdevimab, sold under the brand name REGEN‑COV among others, is a combination medicine used for the treatment and prevention of COVID19. It consists of two human monoclonal antibodies, casirivimab and imdevimab that must be mixed together and administered as an infusion or subcutaneous injection. The combination of two antibodies is intended to prevent mutational escape. It is also available as a co-formulated product. It was developed by the American biotechnology company Regeneron Pharmaceuticals.
Key facts
- Drug.type
- mab
- Drug.image
- File:REGN-COV2 binding SARS-CoV-2 spike protein.png
- Drug.caption
- REGN10933 (blue) and REGN10987 (orange) bound to SARS-CoV-2 spike protein (pink). From .
- Drug.component1
- Casirivimab
- Drug.class1
- Monoclonal antibody against spike protein of SARS-CoV-2
- Drug.component2
- Imdevimab
- Drug.class2
- Monoclonal antibody against spike protein of SARS-CoV-2
- Drug.tradename
- REGN-COV, Ronapreve
- Drug.MedlinePlus
- a620063
- Drug.DailyMedID
- Casirivimab
- Drug.pregnancy_AU
- B2
- Drug.routes_of_administration
- Intravenous, subcutaneous injection
- Drug.ATC_prefix
- None
- Drug.ATC_suffix
- BD07
- Drug.legal_AU
- S4
- Drug.legal_CA
- Rx-only
- Drug.legal_CA_comment
- / Schedule D
- Drug.legal_UK
- POM
via Wikipedia infobox
~10 min read
Encyclopedic overview
11 sectionsContents
- Medical uses
- Deployment
- Society and culture
- Economics
- Legal status
- Research
- COVID-19
- Trials
- References
- Further reading
- External links
Casirivimab/imdevimab, sold under the brand name REGEN‑COV among others, is a combination medicine used for the treatment and prevention of COVID19. It consists of two human monoclonal antibodies, casirivimab and imdevimab that must be mixed together and administered as an infusion or subcutaneous injection. The combination of two antibodies is intended to prevent mutational escape. It is also available as a co-formulated product. It was developed by the American biotechnology company Regeneron Pharmaceuticals.
The most common side effects include allergic reactions, which include infusion related reactions, injection site reactions, brief pain, weakness and others.
Excerpted from Wikipedia’s “casirivimab/imdevimab” article, available under the CC BY-SA 4.0 licence.